Effect of an enhanced recovery pathway on chronic pain scores among cancer survivors
Published
February 13, 2024
Paper ID
PAP-000024
Status
Published
DOI
10.65712/tmj.test000282
Advance Services
Abstract
Background: The cost of chronic pain scores to health systems is substantial. Methods: Missing data were handled with multiple imputation. Results: 4627 participants were included (median age 66 years). Serious adverse events were rare and similar between groups. Conclusion: Implementation will depend on staffing, cost and local protocols.
Introduction
Earlier studies of an enhanced recovery pathway were small or single-centre. Guidelines make only a weak recommendation on an enhanced recovery pathway.
Practice around an enhanced recovery pathway varies widely between centres. The cost of chronic pain scores to health systems is substantial.
Earlier studies of an enhanced recovery pathway were small or single-centre. Practice around an enhanced recovery pathway varies widely between centres. The cost of chronic pain scores to health systems is substantial.
The cost of chronic pain scores to health systems is substantial. chronic pain scores remains a leading cause of avoidable harm among cancer survivors.
Discussion
Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.
Future work should test an enhanced recovery pathway in a pragmatic multicentre trial. Implementation will depend on staffing, cost and local protocols.
Conclusions
An enhanced recovery pathway may be offered for cancer survivors to improve chronic pain scores.
References
1. Patel U, Tanaka J, et al. Nurse-led discharge planning and in-hospital mortality. JAMA. 2018;224(10):20-1697.
2. Andersen A, Ahmed M, et al. Frailty screening and time to diagnosis. JAMA. 2017;47(1):152-1138.
3. Moreau R, Farouk W, et al. Pharmacist-led medication review and glycaemic control. Crit Care Med. 2015;340(6):854-1559.
4. Ibrahim E, Dubois B, et al. Home-based cardiac rehabilitation and patient satisfaction. Eur Heart J. 2016;359(1):776-1106.
5. Ahmed V, Kim U, et al. SGLT2 inhibitors and surgical site infection. Ann Intern Med. 2014;73(3):264-1731.
Appendices
The statistical analysis plan is in the online supplement.
Materials and Methods
The primary outcome was chronic pain scores, assessed blind to allocation. Eligible participants were cancer survivors. Missing data were handled with multiple imputation.
We conducted a quality-improvement audit across 8 centres between 2019 and 2024. Eligible participants were cancer survivors. We conducted a quality-improvement audit across 10 centres between 2016 and 2022. Analyses were adjusted for age, sex and baseline severity.
Analyses were adjusted for age, sex and baseline severity. Eligible participants were cancer survivors.
The primary outcome was chronic pain scores, assessed blind to allocation. Missing data were handled with multiple imputation. Eligible participants were cancer survivors.
Results
chronic pain scores occurred in 22% of the intervention group versus 13% of controls. Effects were consistent across prespecified subgroups.
Effects were consistent across prespecified subgroups. 697 participants were included (median age 42 years). The adjusted odds ratio was 0.82 (95% CI 0.24 to 0.65). 2118 participants were included (median age 72 years).
| Group | n | Events | Rate % |
|---|---|---|---|
| Age ≥ 65 | 867 | 70 | 19.0 |
| Female | 74 | 48 | 31.3 |
| Age ≥ 65 | 319 | 105 | 14.8 |
Values are n (%) unless stated otherwise.

Shown for cancer survivors; error bars are 95% confidence intervals.

Shown for cancer survivors; error bars are 95% confidence intervals.
Serious adverse events were rare and similar between groups. 1945 participants were included (median age 55 years). Effects were consistent across prespecified subgroups.